Tag Archives: vorapaxar

CORONARY: off-pump and on-pump CABG similar The largest trial ever to compare off-pump and on-pump coronary artery bypass surgery (CABG) has shown no difference between the two techniques in terms of the primary composite end point. There were, however, some differences in certain end points, leading to the suggestion that the decision as to which approach to choose could be individualised with each patient. Table 1. Main results from the CORONARY trial The CORONARY trial enrolled 4,752 patients who were randomised to off-pump or on-pump surgery. At 30 days the primary end point – a composite of death, myocardial infraction (MI), kidney fai

Vorapaxar is a protease-activated receptor 1 (PAR-1) antagonist that blocks thrombin-induced platelet activation and therefore inhibits platelets by a different mechanism to other available antiplatelet drugs. The TRA-2P study involved 26,449 patients with myocardial infarction (MI), ischaemic stroke, or peripheral vascular disease. Addition of vorapaxar to standard of care is reported to have significantly reduced the risk of cardiovascular death/MI/stroke/urgent coronary revascularisation (composite primary end point), but at the cost of increased bleeding. However, there was a lower risk of intracranial haemorrhage in patients without a hi